A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms PIONEER6
- Sponsors Novo Nordisk
- 21 Dec 2017 Planned primary completion date changed from 16 Apr 2018 to 16 Oct 2018.
- 21 Nov 2017 According to a Novo Nordisk media release, the trial is expected to be completed in 2018.
- 13 Sep 2017 Status changed from recruiting to active, no longer recruiting.